Xenical Capsule
FDA Label NDC 61269-460

28 label sections · Submitted to the FDA by H2-pharma Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by H2-pharma Llc for the product Xenical (NDC 61269-460). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, recommended dosage and administration, 3 dosage forms and strengths, 4 contraindications, 5.1 loss of effect of certain medications and dietary supplements with coadministration of xenical, 5.2 liver injury, 5.3 oxalate nephrolithiasis and oxalate nephropathy with renal failure, 5.4 acute gallbladder disease, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

1 Indications And Usage

XENICAL is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:

  • adults and pediatric patients aged 12 years and older with obesity.
  • adults with overweight in the presence of at least one weight-related comorbid condition.

The recommended dosage of XENICAL is one 120 mg capsule taken orally three times a day with each main meal containing fat (during or up to 1 hour after the meal). Dosages above 120 mg three times a day have not been shown to provide additional benefit.

  • Take XENICAL with a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat [see Warnings and Precautions (5.5) and Clinical Studies (14.1)].
  • Distribute the daily intake of fat, carbohydrate, and protein over three main meals.
  • Skip the dose of XENICAL if a meal is missed or contains no fat. Resume XENICAL at the next scheduled main meal containing fat.
  • Administer a multivitamin containing fat-soluble vitamins once daily at least 2 hours before or 2 hours after administration of XENICAL, or at bedtime [see Warnings and Precautions (5.1) and Drug Interactions (7)].

3 Dosage Forms And Strengths

Capsules: 120 mg, turquoise, imprinted with “XENICAL 120” in black ink.

4 Contraindications

XENICAL is contraindicated in patients with:

  • chronic malabsorption syndrome [see Warnings and Precautions (5.1)]
  • cholestasis
  • known hypersensitivity to orlistat or any of the inactive ingredients in XENICAL. Serious hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported with XENICAL [see Adverse Reactions (6.2)].

5.1 Loss Of Effect Of Certain Medications And Dietary Supplements With Coadministration Of Xenical

Serious outcomes due to the loss of effect of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene have been reported with coadministration of XENICAL. Do not coadminister XENICAL simultaneously with cyclosporine or levothyroxine [see Drug Interactions (7)]. Administer cyclosporine 3 hours after the administration of XENICAL. Administer levothyroxine and XENICAL at least 4 hours apart. Administer a multivitamin supplement at least 2 hours before or 2 hours after the administration of XENICAL, or at bedtime. Monitor the effectiveness of cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene, as clinically indicated [see Drug Interactions (7) and Clinical Pharmacology (12.3)].

5.2 Liver Injury

There have been rare postmarketing reports of severe liver injury with hepatocellular necrosis or acute hepatic failure in patients treated with XENICAL, with some of these cases resulting in liver transplant or death [see Adverse Reactions (6.2)]. Instruct patients to report any symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, dark urine, light-colored stools, or right upper quadrant pain) while taking XENICAL. When these symptoms occur, immediately discontinue XENICAL and other suspected medications and obtain liver function tests, including ALT and AST levels.

5.3 Oxalate Nephrolithiasis And Oxalate Nephropathy With Renal Failure

XENICAL may increase levels of urinary oxalate. Cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure have been reported [see Adverse Reactions (6.2)]. Monitor renal function when prescribing XENICAL to patients at increased risk for oxalate nephropathy, including patients with renal impairment and in those with a history of hyperoxaluria or calcium oxalate nephrolithiasis. Discontinue XENICAL in patients who develop oxalate nephropathy.

5.4 Acute Gallbladder Disease

Acute events of gallbladder disease such as cholelithiasis, have been reported in clinical trials and during the postmarketing experience with XENICAL. In a 4-year clinical trial of XENICAL, cholelithiasis was reported in 2.9% (47/1649) of XENICAL-treated patients versus 1.8% (30/1655) of placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.

5.5 Gastrointestinal Events

Gastrointestinal events may increase when XENICAL is taken with a diet high in fat (>30% total daily calories from fat) [see Adverse Reactions (6.1)]. Advise patients receiving XENICAL to adhere to dietary guidelines [see Dosage and Administration (2)]. The daily intake of fat should be distributed over three main meals. If XENICAL is taken with any one meal very high in fat, the possibility of gastrointestinal effects increases.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in patients.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of XENICAL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to XENICAL exposure.

  • Immune System: Rare cases of hypersensitivity. Signs and symptoms have included pruritus, rash, urticaria, angioedema, bronchospasm and anaphylaxis. Very rare cases of bullous eruption.
  • Gastrointestinal:Pancreatitis; lower gastrointestinal bleeding.
  • Hepatobiliary: Hepatitis that may be serious, and hepatic failure, with some of these cases resulting in liver transplant or death [see Warnings and Precautions (5.2)]; cholelithiasis [see Warnings and Precautions (5.4)]; increases in transaminases and alkaline phosphatase.
  • Skin and Subcutaneous Tissue: Leukocytoclastic vasculitis. Clinical signs include palpable purpura, maculopapular lesions, or bullous eruption.
  • Renal and Urinary: Acute oxalate nephropathy and hyperoxaluria in patients with or at risk for renal disease.

8.2 Lactation

Risk Summary

There are no data on the presence of XENICAL or its metabolite in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for XENICAL and any potential adverse effects on the breastfed infant from XENICAL or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of XENICAL in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term have been established in pediatric patients aged 12 years and older with obesity. Use of XENICAL in this indication is supported by a 54-week randomized, placebo-controlled trial in 539 pediatric patients aged 12 years and older with obesity (defined as a baseline BMI that was 2 units greater than the US weighted mean for the 95th percentile based on age and sex) [see Clinical Pharmacology (12.2), Clinical Studies (14.2)] and from trials in adult patients with obesity [see Clinical Studies (14.1)]. Adverse reactions with XENICAL treatment in pediatric patients aged 12 years and older were generally similar to those reported in adults [see Adverse Reactions (6.1)].

The safety and effectiveness of XENICAL have not been established in pediatric patients less than 12 years of age.

8.5 Geriatric Use

Clinical studies of XENICAL did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients [see Clinical Studies (14.1)] .

10 Overdosage

In the event of an overdose of XENICAL, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. Observe patients for 24 hours if an overdose of XENICAL occurs. Based on human and animal studies, systemic effects attributable to the lipase-inhibiting properties of XENICAL should be rapidly reversible.

11 Description

XENICAL (orlistat) is an intestinal lipase inhibitor.

Orlistat is (S)-2-formylamino-4-methyl-pentanoic acid (S)-1-[[(2S, 3S)-3-hexyl-4-oxo-2-oxetanyl] methyl]-dodecyl ester. Its empirical formula is C29H53NO5, and its molecular weight is 495.7. It is a single diastereomeric molecule that contains four chiral centers, with a negative optical rotation in ethanol at 529 nm. The structure is:

Chemical Structure (Xenical 02)

Chemical Structure (Xenical 02)

Orlistat is a white to off-white crystalline powder. Orlistat is practically insoluble in water, freely soluble in chloroform, and very soluble in methanol and ethanol. Orlistat has no pKa within the physiological pH range.

Each XENICAL capsule contains a pellet formulation consisting of 120 mg of the active ingredient, orlistat, as well as the inactive ingredients microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium starch glycolate, and talc. The capsule shell contains FD&C Blue No. 2 (with black printing ink containing black iron oxide, pharmaceutical grade shellac, potassium hydroxide, propylene glycol, and strong ammonium solution), gelatin, and titanium dioxide.

12.1 Mechanism Of Action

Orlistat is a reversible inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. Undigested triglycerides are not absorbed, resulting in a caloric deficit.

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

In two-year carcinogenicity studies, orlistat was given to rats and mice at doses up to 1,000 mg/kg/day and 1,500 mg/kg/day, respectively. Orlistat was not carcinogenic up to the highest doses tested in rats and mice, representing 46 times and 38 times the maximum recommended human dose, respectively, based on area under concentration vs time curve of total drug-related material.

Orlistat had no detectable mutagenic or genotoxic activity as determined by the Ames test, a mammalian forward mutation assay (V79/HPRT), an in vitro clastogenesis assay in peripheral human lymphocytes, an unscheduled DNA synthesis assay (UDS) in rat hepatocytes in culture, and an in vivo mouse micronucleus test.

No effects on fertility were observed in male and female rats given orlistat oral doses up to 400 mg/kg/day corresponding to 12 times MRHD, based on body surface area (mg/m2).

14.1 Weight Reduction And Long-Term Maintenance Trials In Adults With Obesity Or Overweight

Overview of Clinical Trials in Adults

The effects of XENICAL 120 mg administered orally three times a day on weight reduction and long-term maintenance of body weight in conjunction with a reduced calorie diet that provided approximately 30% of calories from fat were assessed in seven multicenter, double-blind, placebo-controlled clinical trials of 1- to 2-years duration, and in a 4-year trial. The seven trials included 1,466 patients treated with placebo, 1,913 patients treated with XENICAL 120 mg orally three times a day, and 809 patients treated with unapproved dosages of XENICAL. Patients were 17 to 78 years of age; 80% were female, 91% White, 6% Black or African American, 2% were of Hispanic or Latino ethnicity, and 1% were of other races. Six of the trials enrolled patients without type 2 diabetes mellitus (Trials 1-6) and one of the trials enrolled a population of patients with type 2 diabetes mellitus (Trial 7). The 4-year trial (Trial 8) included 3,304 patients; age range 30 to 58 years; 55% were female; 99% were White and 1% other races. This trial included a subset of patients with abnormal glucose at baseline.

Effect of XENICAL on Body Weight After 1 Year of Treatment

A total of 2,680 obese patients were randomly assigned to receive either placebo (n = 1,119) or XENICAL 120 mg orally three times a day (n = 1,561) for at least one year in five clinical trials. Baseline mean body weight was approximately 100 kg in the pool of Trials 1-5. A total of 1,072 (69%) patients treated with XENICAL and 701 (63%) patients treated with placebo completed 1 year of treatment. After 1 year of treatment, the mean percent weight loss difference between XENICAL-treated patients and placebo-treated patients was 3%. Greater proportions of patients treated with XENICAL achieved 5% and 10% weight loss than those treated with placebo as shown in Table 5.

Table 5              Percentage of Patients Losing ≥5% and ≥10% of Body Weight from Randomization After 1 Year of Treatmenta

Trial Number

≥5% Weight Loss

≥10% Weight Loss

Placebo

N

XENICAL

N

p-value

Placebo

N

XENICAL

N

p-value

1

21.3%

108

35.5%

110

0.021

6.5%

108

16.4%

110

0.022

2

27.4%

340

54.8%

343

<0.001

8.2%

340

24.8%

343

<0.001

3

26.3%

236

50.6%

241

<0.001

11.9%

236

22.8%

241

0.02

4b

16.0%

212

37.1%

210

<0.001

3.8%

212

19.5%

210

<0.001

5

22.4%

223

42.6%

657

<0.001

9.9%

223

17.7%

657

0.006

a modified intent to treat – last observation carried forward (MITT-LOCF)

b All trials, with the exception of Trial 4, were conducted at centers specialized in treating obesity and complications of obesity. Trial 4 was conducted with primary care physicians.

Effect of XENICAL on Anthropometry and Cardiometabolic Parameters

The changes in anthropometry and cardiometabolic parameters at the end of the 1-year treatment period in the all trials population (Trials 1-5) are presented in Table 6.

Table 6              Mean Changes in Anthropometry and Cardiometabolic Parameters from Randomization Following 1 Year of Treatmenta,bin the All Trials Population of Clinical Trials 1 – 5

Parameter

Placebo

XENICAL

Total Cholesterol

+5.0%

-2.0%

LDL-Cholesterol

+5.0%

-4.0%

HDL-Cholesterol

+12.8%

+9.3%

Triglycerides

+2.9%

+1.34%

Systolic Blood Pressure (mmHg)

+0.58

-1.01

Diastolic Blood Pressure (mmHg)

+0.46

-1.19

Waist Circumference (cm)

-4.04

-6.45

a modified intent to treat – last observation carried forward (MITT-LOCF)

b Change from baseline at 1 year of treatment.

Effect of XENICAL on Body Weight After 2 Years of Treatment

The treatment effects of XENICAL were examined for 2 years in four trials (Trials 2-5). The 2-year analysis population included a total of 1,122 patients who were randomly assigned to receive either placebo (n = 516) or XENICAL (n = 606). Patients were included only if they had been randomly assigned to receive the same treatment for both years – either placebo, or XENICAL 120 mg orally three times a day– and only if they had completed the first year of treatment. At the end of year 1, the patients’ diets were reviewed and changed where necessary. The diet prescribed in the second year was designed to maintain a patient’s current weight. The mean baseline body weight was 99 kg.

The proportion of patients (pooled from four clinical trials) who completed 1 year of treatment and went on to complete a second year of therapy was 74% for XENICAL (n = 450) and 76% for placebo (n = 392). Pooled data from four clinical trials indicate that the mean weight loss difference between XENICAL 120 mg three times a day and placebo treatment groups at year 2 in those patients who completed 1 year of treatment (LOCF) was 3% The percentages of patients achieving a ≥5% and ≥10% weight loss after 2 years are shown in Table 7.

Table 7              Percentage of Patients Losing ≥5% and ≥10% of Body Weight from Randomization After 2 Years of Treatmenta

Trial Number

≥5% Weight Loss

≥10% Weight Loss

Placebo

N

XENICAL

N

p-value

Placebo

N

XENICAL

N

p-value

2

23.6%

123

45.1%

133

<0.001

6.5%

123

24.8%

133

<0.001

3

27.2%

158

43.3%

178

0.002

9.5%

158

18.0%

178

0.025

4b

15.0%

113

25.0%

148

0.049

3.5%

113

16.9%

148

0.001

5

27.9%

122

34.0%

147

0.279

11.5%

122

17.7%

147

0.154

a modified intent to treat – last observation carried forward (MITT-LOCF)

b All trials, with the exception of Trial 4, were conducted at centers specializing in treating obesity or complications of obesity. Trial 4 was conducted with primary care physicians.

The relative differences in anthropometry and cardiometabolic parameters between treatment with XENICAL and placebo were similar to the results following 1 year of therapy for total cholesterol, LDL-cholesterol, triglycerides, diastolic blood pressure, and waist circumference. The relative differences between treatment groups for HDL cholesterol and systolic blood pressure were less than that observed in the year one results.

Effect of XENICAL on Body Weight After 4 Years of Treatment

In the 4-year double-blind, placebo-controlled trial (Trial 8), the effects of XENICAL on body weight were compared to placebo in 3,304 patients with obesity who had either normal or impaired blood glucose tolerance at baseline. Mean baseline body weight was 110.5 kg and mean BMI was 37.4 kg/m2. A total of 564 patients (34%) of the 1,655 patients, who were randomized to the placebo group, and 850 patients (52%) of the 1,649 patients, who were randomized to the XENICAL group, completed the 4-year study.

At the end of the study, the mean percent weight loss in the placebo group was -2.75% compared with -5.17% in the XENICAL group (p<0.001). Figure 2 presents mean percent change from baseline body weight observed for patients completing each study visit.

Forty-five percent of the placebo patients and 73% of the XENICAL patients lost ≥5% of their baseline body weight, and 21% of the placebo patients and 41% of the XENICAL patients lost ≥10% of their baseline body weight following the first year of treatment. Following 4 years of treatment, 28% of the placebo patients and 45% of the XENICAL patients lost ≥5% of their baseline body weight and 10% of the placebo patients and 21% of the XENICAL patients lost ≥10% of their baseline body weight. After 4 years of treatment, the mean percent difference in weight loss between XENICAL-treated patients and placebo was 2.5%.

Figure 2             Mean Change from Baseline Body Weight (%) Over Timea

Figure 2 (Xenical 07)

Figure 2 (Xenical 07)

a Observed values for patients completing each scheduled visit.

Effect of XENICAL on Body Weight in Adults with Type 2 Diabetes Mellitus and Obesity or Overweight

A 1-year double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus with obesity or overweight (n = 321) stabilized on sulfonylureas was conducted (Trial 7). Mean baseline body weight was 99.7 kg and mean BMI was 34.3 kg/m2. Following 1 year of treatment, the mean change in body weight was 6.19 kg with XENICAL and 4.31 kg with placebo (p≤0.05). Thirty percent (30%) of patients treated with XENICAL achieved at least a 5% or greater reduction in body weight from randomization compared to 13% of the placebo-treated patients (p<0.001).

The changes in HbA1c and cardiometabolic parameters at the end of the 1-year treatment period in Trial 7 are presented in Table 8.

Table 8              Mean Changes in HbA1c and Cardiometabolic Parameters from Randomization Following 1 Year of Treatmenta

Parameter

Placebo

XENICAL

Total Cholesterol

+9.0

-0.9

LDL-Cholesterol

+9.5

-3.0

HDL-Cholesterol

+8.6

+6.5

Triglycerides

+16.2

+2.5

HbA1c (%)

+0.28

-0.18

Systolic Blood Pressure (mmHg)

+4.3

+0.6

Diastolic Blood Pressure (mmHg)

-0.5

-0.5

a modified intent to treat – last observation carried forward (MITT-LOCF)

14.2 Weight Reduction And Long-Term Maintenance Trial In Pediatric Patients Aged 12 Years And Older With Obesity

The effects of XENICAL on weight reduction and long-term maintenance were assessed in a 54-week multicenter, double-blind, placebo-controlled study in 539 pediatric patients aged 12 years and older with obesity (357 receiving XENICAL 120 mg three times a day, 182 receiving placebo). A similar percentage of patients in each treatment group (placebo 64%, XENICAL 65%) completed the study. The mean baseline BMI was 36 kg/m2 in both treatment groups, and the mean baseline body weight was 98 kg among XENICAL-treated patients and 95 kg for placebo-treated patients. All study participants had a baseline BMI that was 2 units greater than the US weighted mean for the 95th percentile based on age and sex. The primary endpoint was percent change from baseline BMI. The mean age was 13.5 years. Most of the patients were White (XENICAL 75%, placebo 78%), Black or African American (XENICAL 19%, placebo 14%) and females (XENICAL 65%, placebo 71%).

During the study, all patients were instructed to take a multivitamin containing fat-soluble vitamins at least 2 hours before or after ingestion of XENICAL. Patients were instructed to maintain a reduced-calorie diet that provided 30% of calories from fat, 50% of calories from carbohydrate, and 20% of calories as protein. In addition, all patients were enrolled in a behavior modification program and offered counseling on physical activity.

At week 54, the least squared mean change from baseline in BMI was -0.55 kg/m2 in XENICAL-treated patients and +0.31 kg/m2 in placebo-treated patients (p=0.001).

The percentages of patients achieving ≥5% and ≥10% reduction in BMI and body weight after 52 weeks of treatment for the intent-to-treat population are presented in Table 9.

Table 9              Percentages of Patients with ≥5% and ≥10% Decrease in Body Mass Index and Body Weight After 1 Year of Treatmenta

≥5% Decrease

≥10% Decrease

Placebo

N

XENICAL

N

Placebo

N

XENICAL

N

BMI

15.7%

178

26.5%

347

4.5%

178

13.3%

347

Body Weight

11.7%

180

19.0%

348

3.3%

180

9.5%

348

a modified intent to treat – last observation carried forward (MITT-LOCF)

16 How Supplied/Storage And Handling

XENICAL is a turquoise, hard-gelatin capsule containing pellets of powder.

XENICAL 120 mg Capsules: Turquoise, two-piece, No. 1 opaque hard-gelatin capsule imprinted with XENICAL 120 in black ink — bottle of 90 (NDC 61269-460-90).

Storage And Handling

Storage and Handling

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep bottle tightly closed.

17 Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Loss of Effect of Certain Medications and Dietary Supplements with Coadministration of XENICAL

Advise patients taking cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, antiretroviral drugs, certain fat-soluble vitamins, and beta carotene that XENICAL may reduce their effectiveness [see Warnings and Precautions (5.1) and Drug Interactions (7)].

Liver Injury

Inform patients of the risk of liver injury and educate patients on the signs and symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, dark urine, light-colored stools, or right upper quadrant pain). Instruct patients to contact their health care provider if they experience signs or symptoms of hepatic dysfunction [see Warnings and Precautions (5.2)].

Oxalate Nephrolithiasis and Oxalate Nephropathy with Renal Failure

Inform patients of the potential risk for oxalate nephrolithiasis and oxalate nephropathy and explain the associated signs and symptoms, including of renal failure. Instruct patients to contact their health care provider if they experience signs or symptoms of oxalate nephrolithiasis or oxalate nephropathy [see Warnings and Precautions (5.3)].

Acute Gallbladder Disease

Inform patients of the risk of acute gallbladder disease. Instruct patients to contact their health care provider for appropriate clinical follow-up if gallbladder disease is suspected [see Warnings and Precautions (5.4)].

Gastrointestinal Events

Inform patients of the risk of the commonly-observed gastrointestinal adverse events associated with the use of XENICAL which include oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation, and fecal incontinence. Advise patients to adhere to dietary guidelines to distribute the daily intake of fat over three main meals [see Dosage and Administration (2)]. Advise patients that if XENICAL is taken with any one meal very high in fat, the possibility of gastrointestinal effects increases [see Warnings and Precautions (5.5)].

Spl Patient Package Insert

Patient Information

XENICAL®(zen'i-cal)

(orlistat)

capsules, for oral use

Read this Patient Information before you start taking XENICAL and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

What is XENICAL?

XENICAL is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.

It is not known if XENICAL is safe and effective in children under 12 years old.

Do not take XENICAL if you:

  • have ongoing problems absorbing nutrients from food (chronic malabsorption)
  • have a bile flow problem (cholestasis)
  • are allergic to orlistat or any of the ingredients in XENICAL. See the end of this leaflet for a complete list of ingredients in XENICAL

Before you take XENICAL, tell your healthcare provider about all of your medical conditions, including if you:

  • have liver problems
  • have kidney problems
  • have problems with your thyroid
  • have eating problems such as anorexia or bulimia
  • have diabetes
  • have a seizure disorder (epilepsy)
  • have an abnormal heart rhythm (arrhythmia)
  • have the human immunodeficiency virus (HIV)
  • are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if XENICAL passes into your breast milk.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    XENICAL and other medicines may affect each other causing side effects. XENICAL may affect the way other medicines work, and other medicines may affect the way XENICAL works.

    Especially tell your healthcare provider if you are taking the following medicines because they may not work as well while you take XENICAL:

    • cyclosporine
    • beta carotene or
    • fat soluble vitamins (A, D, E, K)
    • levothyroxine
    • warfarin
    • amiodarone
    • medicines used to treat seizures (antiepileptic). Talk to your healthcare provider right away if your seizures happen more often or get worse while you take XENICAL.
    • antiretroviral medicines
    • Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

How should I take XENICAL?

  • Take XENICAL exactly as your healthcare provider tells you to take it.
  • Your healthcare provider will tell you how much XENICAL to take and when to take it.
  • Take XENICAL with your main meals that have fat in them or up to 1 hour after your meal.
  • If you miss a meal or have a meal that does not have fat in it, you can skip your dose of XENICAL. Take your next dose of XENICAL at your next scheduled main meal that has fat in it.
  • If you take cyclosporine, take XENICAL 3 hours after you take cyclosporine.
  • Take a multivitamin at least 2 hours before or after you take XENICAL, or at bedtime.
  • If you take levothyroxine, take XENICAL and levothyroxine at least 4 hours apart.
  • Spread your daily fat, carbohydrates and protein over three main meals.
  • Take XENICAL with a nutritionally balanced, low-calorie diet that has no more than about 30% of calories from fat (see Table 1). Taking XENICAL with any meal high in fat (more than 30% fat) may make the common side effects worse.
  • Table 1. Recommended Daily Grams of Fat Based on Daily Calorie Intake

    IF YOUR DAILY CALORIE INTAKE IS:

    THE RECOMMENDED DAILY GRAMS OF FAT (in a 30% fat diet) ARE:

    • 1500 calories - 50 grams fat
    • 1600 calories - 53 grams fat
    • 1800 calories - 60 grams fat
    • 2000 calories - 67 grams fat
    • If you take too much XENICAL, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

      What are the possible side effects of XENICAL?

      XENICAL may cause serious side effects, including:

      • lowered absorption of certain vitamins and medicines in your body. See How should I take XENICAL?
      • severe liver problems. Stop taking XENICAL and call your healthcare provider right away if you have the following symptoms of liver problems:
      • o  loss of appetite

        o  itchy skin

        o  yellowing of your skin or the white part of your eyes

        o  amber-colored urine

        o  light-colored bowel movements (stools)

        o  pain in the upper right portion of your stomach

        • kidney problems. Your healthcare provider may do certain tests to check your kidney function during treatment with XENICAL. Call your healthcare provider right away if you have the following symptoms of kidney problems:
        • o swelling, especially of the legs and feet

          o little or no urine output

          o frequent or painful urination

          o blood in the urine

          o loss of appetite, nausea and vomiting

          o severe pain in the back, belly or groin

          • gallbladder problems (gallstones). Call your healthcare provider right away if you have the following symptoms of gallstones:
          • o  pain in the upper right portion of your stomach

            o  nausea

            o  vomiting

            • stomach problems. If you take XENICAL with a meal that is too high in fat it may increase your chance of having stomach problems. If you take XENICAL with any one meal that is very high in fat the chances that you will have stomach problems will increase. See the most common side effects of XENICAL. Follow the diet guidelines in the How should I take XENICAL section of this patient information leaflet.
            • The most common side effects of XENICAL include:

              • oily rectal discharge that may be clear or have an orange or brown color
              • passing gas with oily discharge that may be clear or have an orange or brown color
              • urgent need to have a bowel movement
              • oily or fatty stools
              • increased number of bowel movements
              • being unable to control your bowel movements
              • These are not all the possible side effects of XENICAL. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store XENICAL?

  • Store XENICAL at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep XENICAL in a tightly closed container.
  • Keep XENICAL and all medicines out of the reach of children.

General information about the safe and effective use of XENICAL

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use XENICAL for a condition for which it was not prescribed. Do not give XENICAL to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about XENICAL that is written for health professionals.

For more information, call the Safety Call Center at 1-888-236-5445.

What are the ingredients in XENICAL? Active Ingredient: orlistat

Inactive Ingredients: microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium starch glycolate, and talc. Turquoise capsule shell: FD&C Blue No. 2 (with black printing ink containing black iron oxide, pharmaceutical grade shellac, potassium hydroxide, propylene glycol, and strong ammonium solution), gelatin, and titanium dioxide.

XENICAL® is a registered trademark of CHEPLAPHARM Arzneimittel GmbH.

Licensed by:

CHEPLAPHARM Arzneimittel GmbH Ziegelhof 24, 17489 Greifswald, Germany

Distributed by:

H2-Pharma, LLC

611 Industrial Park Blvd, Montgomery, AL 36117, USA

© 2026 CHEPLAPHARM Arzneimittel GmbH.

All rights reserved.

This Patient Information has been approved by the U.S. Food and Drug Administration                                            Revised 9/2026

* Please review the disclaimer below.